LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Glaukos Corp

Gesloten

SectorGezondheidszorg

95.31 1.71

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

93.19

Max

96.31

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.5M

-20M

Verkoop

17M

124M

Winstmarge

-15.837

Werknemers

995

EBITDA

-513K

-21M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+36.19% upside

Dividenden

By Dow Jones

Volgende Winsten

3 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-173M

5.3B

Vorige openingsprijs

93.6

Vorige sluitingsprijs

95.31

Nieuwssentiment

By Acuity

40%

60%

132 / 372 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Glaukos Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 aug 2025, 22:51 UTC

Winsten

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 aug 2025, 23:57 UTC

Winsten

Trip.com Group 1H Rev $4.01B

27 aug 2025, 23:57 UTC

Winsten

Trip.com Group 1H Adj EPS $1.84

27 aug 2025, 23:57 UTC

Winsten

Trip.com Group 1H EPS $1.82

27 aug 2025, 23:50 UTC

Marktinformatie

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 aug 2025, 23:39 UTC

Winsten

Correction to Nvidia Earnings Article -- WSJ

27 aug 2025, 22:59 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 aug 2025, 22:59 UTC

Marktinformatie

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 aug 2025, 22:58 UTC

Winsten

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 aug 2025, 22:57 UTC

Winsten

South32 FY Free Cash Flow $192 Million

27 aug 2025, 22:56 UTC

Winsten

South32 FY Total Capital Expenditure $1.35 Billion

27 aug 2025, 22:56 UTC

Winsten

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 aug 2025, 22:55 UTC

Winsten

South32 Net Cash $123 Million at June 30

27 aug 2025, 22:54 UTC

Winsten

South32: Focused on Maintaining Strong Operating Momentum

27 aug 2025, 22:53 UTC

Winsten

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 aug 2025, 22:53 UTC

Winsten

South32 Extends Capital Management Program for 12 Months

27 aug 2025, 22:52 UTC

Winsten

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 aug 2025, 22:51 UTC

Winsten

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 aug 2025, 22:51 UTC

Winsten

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 aug 2025, 22:50 UTC

Winsten

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 aug 2025, 22:50 UTC

Winsten

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 aug 2025, 22:45 UTC

Winsten

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 aug 2025, 22:44 UTC

Winsten

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 aug 2025, 22:44 UTC

Winsten

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 aug 2025, 22:43 UTC

Winsten

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 aug 2025, 22:43 UTC

Winsten

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 aug 2025, 22:42 UTC

Winsten

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 aug 2025, 22:42 UTC

Winsten

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 aug 2025, 22:40 UTC

Winsten

Sandfire Resources Net Debt $123 Million at June 30

27 aug 2025, 22:40 UTC

Winsten

Sandfire Resources FY Underlying Ebitda $527.7 Million

Peer Vergelijking

Prijswijziging

Glaukos Corp Prognose

Koersdoel

By TipRanks

36.19% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 127.73 USD  36.19%

Hoogste 165 USD

Laagste 92 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Glaukos Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

11

Buy

1

Hold

0

Sell

Technische score

By Trading Central

87.61 / 93Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

132 / 372 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.